Chelsea Therapeutics Announces Reorganization Plan to Boost Stock Value

More news came out of Charlotte, N.C., Tuesday morning when beleaguered Chelsea Therapeutics (CHTP) announced its plans to undergo a complete reorganization of the company, which is to include layoffs, a new executive structure and changes to the Board of Directors, all with the long-term goal of developing more stockholder value, according to a press release.

The layoffs are expected to save the company $3.5 million in salaries over a year, and the layoffs should be completed by the end of the third quarter of 2012. Part of the plan includes not accepting any more patients for the company’s trial of the hypertension drug Northera, which should then produce results by the end of the year.

In other news, company founder, CEO and President Dr. Simon Pedder, announced that he was stepping down from the company effective immediately, and will serve only in an advisory capacity. The same is said for Keith Schmidt, vice president for marketing and sales, who is resigning his post but will remain an advisor to the company. During the search for a new CEO, Joseph G. Oliveto, VP for Operations for the last four years, will serve as interim CEO. In addition, three members of the Board of Directors (including Chairman Kevan Clemens) are stepping down.

While Chelsea is not widely held by hedge funds, this news may be very uncertain for Julian and Felix Baker’s Baker Bros. Advisors, which was invested nearly $5.9 million in Chelsea at the end of March. The next seven hedge funds combined were invested a total of less than $1 million.

“Chelsea Therapeutics has faced tremendous challenges in moving Northera forward through the regulatory process, making these difficult decisions necessary to ensure stockholder value is preserved in the short term and can be built over the long-term,” said Dr. Michael Weiser, the new Chairman of the Board in the wake of Clemens’ resignation, in a press release. ”We believe that this reorganization should allow the Company’s resources and capital to be laser-focused on efficient conclusion of the 306B study and the evaluation of next steps in the regulatory process. In tandem, the Board plans to explore and evaluate all available strategic options to determine the best path forward in the long-term strategic interests of the Company and its stockholders. We remain committed to Northera, a treatment which meets an important unmet need in patients and has a significant record of efficacy and safety in the clinic and in ex-U.S. markets. We would like to thank those employees leaving the Company for their service. We would also like to recognize Dr. Pedder’s years of dedication to Chelsea and his work in helping to advance the Company’s innovative therapies.”

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

The 50 Best Personal Finance Blogs

Most Expensive Apartments in New York City

Bloodiest UFC Fights Ever Fought

Most Expensive Rum Brands in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!